Quest Diagnostics Incorporated logo
DGXQuest Diagnostics Incorporated

Long-Term Debt

The latest quarterly long-term debt is $5.73 Billion with a quarter-over-quarter change of +0.44%. Long-term debt includes bonds, term loans, mortgages, and other borrowings with maturities greater than one year. It represents the company's structural leverage.

Long-Term Debt

DGX Long-Term Debt

$5.73B

Reported quarterly long-term debt; no daily interpolation.

+42.94% 5Y

Current Long-Term Debt

$5.73B

$5.73 Billion

Quarter-over-Quarter Change

+0.44%

vs. $5.70B prior quarter

Historical Data

96

Quarters of data available

Quarterly Long-Term Debt History

PeriodLong-Term DebtQoQ Change% Change
Q1 2026$5.73B+$25.00M+0.44%
Q4 2025$5.70B+$533.00M+10.31%
Q3 2025$5.17B+$2.00M+0.04%
Q2 2025$5.17B$-689.00M-11.76%
Q1 2025$5.86B+$259.00M+4.63%
Q4 2024$5.60B$-49.00M-0.87%
Q3 2024$5.65B+$1.83B+48.01%
Q2 2024$3.82B+$12.00M+0.32%
Q1 2024$3.80B$-606.00M-13.74%
Q4 2023$4.41B+$464.00M+11.76%
Q3 2023$3.95B+$169.00M+4.47%
Q2 2023$3.78B$-198.00M-4.98%
Q1 2023$3.98B$-3.00M-0.08%
Q4 2022$3.98B$-2.00M-0.05%
Q3 2022$3.98B$-3.00M-0.08%
Q2 2022$3.98B$-2.00M-0.05%
Q1 2022$3.98B$-25.00M-0.62%
Q4 2021$4.01B+$4.00M+0.10%
Q3 2021$4.01B$-2.00M-0.05%
Q2 2021$4.01B$-2.00M-0.05%
Q1 2021$4.01B+$22.00M+0.55%
Q4 2020$3.99B+$00.00%
Q3 2020$3.99B$-3.00M-0.08%
Q2 2020$3.99B$-12.00M-0.30%
Q1 2020$4.00B+$67.00M+1.70%
Q4 2019$3.94B+$779.00M+24.68%
Q3 2019$3.16B+$19.00M+0.61%
Q2 2019$3.14B+$38.00M+1.23%
Q1 2019$3.10B$-297.00M-8.74%
Q4 2018$3.40B+$39.00M+1.16%
Q3 2018$3.36B$-14.00M-0.42%
Q2 2018$3.37B$-309.00M-8.39%
Q1 2018$3.68B$-67.00M-1.79%
Q4 2017$3.75B+$24.00M+0.64%
Q3 2017$3.72B$-1.00M-0.03%
Q2 2017$3.73B+$7.00M+0.19%
Q1 2017$3.72B$-3.00M-0.08%
Q4 2016$3.72B$-81.00M-2.13%
Q3 2016$3.80B$-33.00M-0.86%
Q2 2016$3.83B+$95.00M+2.54%
Q1 2016$3.74B+$248.00M+7.10%
Q4 2015$3.49B$-79.00M-2.21%
Q3 2015$3.57B+$3.00M+0.08%
Q2 2015$3.57B$-120.00M-3.25%
Q1 2015$3.69B+$464.00M+14.39%
Q4 2014$3.22B$-508.00M-13.61%
Q3 2014$3.73B$-6.00M-0.16%
Q2 2014$3.74B+$14.00M+0.38%
Q1 2014$3.72B+$635.00M+20.56%
Q4 2013$3.09B$-33.21M-1.06%
Q3 2013$3.12B+$607,000+0.02%
Q2 2013$3.12B$-25.18M-0.80%
Q1 2013$3.15B$-207.22M-6.18%
Q4 2012$3.35B$-21.73M-0.64%
Q3 2012$3.38B$-2.46M-0.07%
Q2 2012$3.38B+$12.93M+0.38%
Q1 2012$3.37B$-5.26M-0.16%
Q4 2011$3.37B+$2.67M+0.08%
Q3 2011$3.37B+$34.92M+1.05%
Q2 2011$3.33B$-261.71M-7.28%
Q1 2011$3.59B+$953.48M+36.10%
Q4 2010$2.64B$-194.74M-6.87%
Q3 2010$2.84B$-137.94M-4.64%
Q2 2010$2.97B+$29.05M+0.99%
Q1 2010$2.94B+$8.00M+0.27%
Q4 2009$2.94B+$59.06M+2.05%
Q3 2009$2.88B$-33,000-0.00%
Q2 2009$2.88B$-199.40M-6.48%
Q1 2009$3.08B$-918,000-0.03%
Q4 2008$3.08B$-332,000-0.01%
Q3 2008$3.08B$-130.88M-4.08%
Q2 2008$3.21B$-169.42M-5.01%
Q1 2008$3.38B+$1.50M+0.04%
Q4 2007$3.38B$-94.54M-2.72%
Q3 2007$3.47B$-73.29M-2.07%
Q2 2007$3.55B+$2.31B+186.29%
Q1 2007$1.24B$-840,000-0.07%
Q4 2006$1.24B+$103,000+0.01%
Q3 2006$1.24B$-1.61M-0.13%
Q2 2006$1.24B+$112,000+0.01%
Q1 2006$1.24B$-14.88M-1.19%
Q4 2005$1.26B+$905.99M+259.30%
Q3 2005$349.40M$-274.75M-44.02%
Q2 2005$624.15M+$64,000+0.01%
Q1 2005$624.09M$-99.94M-13.80%
Q4 2004$724.02M$-247.79M-25.50%
Q3 2004$971.81M+$93,000+0.01%
Q2 2004$971.72M$-86.03M-8.13%
Q1 2004$1.06B+$29.04M+2.82%
Q4 2003$1.03B$-36.43M-3.42%
Q3 2003$1.07B$-30,000-0.00%
Q2 2003$1.07B$-79.18M-6.92%
Q1 2003$1.14B+$347.85M+43.67%
Q4 2002$796.51M$-271,000-0.03%
Q3 2002$796.78M$-24.04M-2.93%
Q2 2002$820.82M
Data as of Friday, June 26, 2026

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.

Secaucus, NJ
55,000 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James E. Davis